Company Profile

Drug Design Methodologies LLC
Profile last edited on: 5/18/2018      CAGE: 7RLZ0      UEI: DH1NULY7F9U4

Business Identifier: Computational solutions for structure based drug design
Year Founded
1998
First Award
2000
Latest Award
2018
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4355 Maryland Avenue Suite 105
Saint Louis, MO 63108
   (314) 652-3411
   cho@newdrugdesign.com
   www.newdrugdesign.com
Location: Single
Congr. District: 01
County: St. Louis city

Public Profile

Drug Design Methodologies is organized around accelerating and de-risking both pharmaceutical and biotechnology pipelines by use of novel software to optimize weak binding drugs and accurately measure drug-target binding The underlying problem with computational drug design is being able accurately to estimate ligand-receptor binding affinity - a complex matter that has hampered the utility of structure-based drug design. Recent advances in GPU driven computing have made it possible to achieve accurate results in reasonable time frames. Calculations are performed using molecular dynamics adequately to sample a suitable thermodynamic path and intermediate states. The measured energies during alchemical transformation are then used tcomputationally to estimate ligand-receptor binding affinity by a number of published techniques - including: Thermodynamic integration; Weighted Histogram Analysis Method; Bennett Acceptance Ratio and Linear Interaction Energy. Whatever the method, the accuracy of the force field used in computing the molecular energies dictates success or failure. Principals of this firm are using different approaches to tackling these situations.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Chris M Ho -- Owner & Chief Scientific Officer

  Garland R Marshall -- Scientific Advisor

  Jay Ponder -- Scientific Advisor

Company News

There are no news available.